Intravitreal Therapy Resolves Macular Edema in Half of Patients with Retinal Vein Occlusion
Investigators also say disorganization of retinal inner layers may play an important role in the development of macular edema.
Anti-VEGF Drugs
Study Shows Why Some Patients Misidentify Their Treatment Eye
Investigators uncover which patients are more likely to misidentify their treatment eye.
Study: Lapses in Intraocular Injections Can Lead to Irreversible Acuity Loss
Researchers found that, while patients who have a lapse in anti-VEGF injections can regain central subfield thickness after missing 12 months of visits, losses to visual acuity are permanent.
Identifying Treatment Nonadherence Factors in nAMD May Improve Outcomes
An investigation uncovers the reasons behind the nearly 60% nonadherence and nonpersistence rate in patients with neovascular age-related macular degeneration after 24 months.
Anti-VEGF Therapy May Not Improve Outcomes in Diabetic Macular Edema
Researchers found that, following anti-VEGF therapy, patients with DME mainted retinal thickness, but lost letters of visual acuity at 2 and 5 year follow-up appointments.
No Differences in Systemic Events Between Anti-VEGF Agents
Investigators assessed whether patients undergoing treatment with anti-VEGF injections for age-related macular degeneration, diabetic retinal disease or retinal venous occlusive disease experienced side effects associated with therapy.
Low Doses of Bevacizumab Tested for Retinopathy of Prematurity
Study suggests that bevacizumab may treat retinopathy of prematurity (ROP) with doses as low as 0.004mg.
Aflibercept for Diabetic Macular Edema: Seeing Dollar Signs
Before the introduction of vascular endothelial growth factor inhibitors, laser photocoagulation was the standard of care for treatment of DME with or without preserved visual acuity.
Brolucizumab Safety Update Issued Following Reports of Ocular Events
Cases of severe vision loss, inflammation, and potential retinal vasculitis following treatment with Beovu (brolucizumab) injection are currently being investigated by the product’s manufacturer Novartis.
-
Loading...
-
Loading...
Next post in Retina & Vitreous
